Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...

The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to ...

Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...

In hemolytic anemia, red blood cells are destroyed faster ... Aplastic anemia usually results in the immune system damaging bone marrow stem cells. Other potential causes include: medications ...

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune ...

Hemolytic anemia occurs when red blood cells are broken up in the bloodstream or in the spleen. It may be due to mechanical problems (leaky heart valves or aneurysms), infections, autoimmune ...

Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to treat symptoms such as pain, inflammation, and fever. It is available over the counter under several brand names — including ...

Considering taking supplements to treat hemolytic anemia? Below is a list of common natural remedies used to treat or reduce the symptoms of hemolytic anemia. Follow the links to read common uses ...

Rilzabrutinib, an investigational oral BTK inhibitor, has received orphan drug designation from the FDA for treating warm autoimmune hemolytic an ...

CD163 is a macrophage receptor that clears hemoglobin-haptoglobin complexes from blood, preventing oxidative damage and also ...